1. Home
  2. NOV vs IMVT Comparison

NOV vs IMVT Comparison

Compare NOV & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOV Inc.

NOV

NOV Inc.

HOLD

Current Price

$17.52

Market Cap

5.7B

Sector

Industrials

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.34

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOV
IMVT
Founded
1862
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.3B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NOV
IMVT
Price
$17.52
$26.34
Analyst Decision
Hold
Buy
Analyst Count
14
9
Target Price
$16.71
$29.13
AVG Volume (30 Days)
3.8M
2.2M
Earning Date
02-04-2026
02-05-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$8,775,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.84
$12.72
52 Week High
$17.84
$27.80

Technical Indicators

Market Signals
Indicator
NOV
IMVT
Relative Strength Index (RSI) 65.27 56.61
Support Level $16.67 $25.78
Resistance Level $17.80 $27.38
Average True Range (ATR) 0.52 1.04
MACD 0.15 -0.12
Stochastic Oscillator 85.98 50.65

Price Performance

Historical Comparison
NOV
IMVT

About NOV NOV Inc.

NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: